XCEL-UMC-BETA

N/A

Report date: 2023/01/12 15:30:17

Base Information

Drug NameXCEL-UMC-BETA

Drug Alias NameMesenchymal stem cells XCEL-UMC-BETAXCEL-UMC-BETA

ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Spinal Cord InjuriesRespiratory Distress Syndrome, Adult

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesBanc De Sang I Teixits

China Registration ClassN/A

Develop Information

Active CompaniesBanc De Sang I Teixits

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Spinal Cord InjuriesRespiratory Distress Syndrome, Adult

Inactive IndicationsN/A

Other Information

ATC CodeN/A